Small mol­e­cules, bi­o­log­ics and now gene ther­a­pies: Ger­many's Evotec adds an­oth­er feath­er to its R&D cap

Ger­man drug dis­cov­ery com­pa­ny Evotec — which has a thriv­ing rolodex of bio­phar­ma part­ners such as Bay­er, Boehringer In­gel­heim, No­var­tis, No­vo Nordisk, Pfiz­er, Sanofi, and Take­da — is now ven­tur­ing in­to gene ther­a­pies.

The com­pa­ny swal­lowed Seat­tle-based Just Bio­ther­a­peu­tics, a com­pa­ny fo­cused on re­duc­ing the cost of man­u­fac­tur­ing pro­tein ther­a­pies last year. It is now set­ting up a ded­i­cat­ed R&D site for gene ther­a­pies in Aus­tria, in an ef­fort to achieve a “modal­i­ty-ag­nos­tic” reper­toire — small mol­e­cules, bi­o­log­ics and now gene ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.